News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Anika Therapeutics (ANIK) Announces U.S. Commercialization Partnership For Hyalomatrix® With Wound Care Leader Medline Industries, Inc.



7/31/2014 11:24:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has entered into a new agreement with Medline Industries, Inc. to commercialize the Company’s advanced wound care product - Hyalomatrix®, in the United States on an exclusive basis through 2019. According to the agreement, Anika will receive product payment and royalty revenues from the sale of the product by Medline. Hyalomatrix® is a biologically-derived matrix for in-growing cells, and has the U.S. Food and Drug Administration marketing clearance.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES